Psma-Hbed-Cc
Recurrence
Novartis PharmaceuticalsradiopharmaceuticalPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Recurrence cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Amsterdam UMC, location VUmc | Phase 3 | B |
Irinotecan Amsterdam UMC, location VUmc | Phase 3 | B |
(+)-VINCRISTINE Kyorin University | Phase 3 | B |
Epirubicin Asha Nayak | Phase 1/2 | CC |
Cyclophosphamide Asha Nayak | Phase 1/2 | CC |
Same molecule, other indications
Psma-Hbed-Cc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →